Gene · 3205
Papers4,255
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
581 to 600 of 4,255
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| 17β-neriifolin from unripe fruits of Cerbera manghas suppressed cell proliferation via the inhibition of HOXA9-dependent transcription and the induction of apoptosis in the human AML cell line THP-1. | J Nat Med | 2023 | 36266527 | PubTator, text mining | PubMed |
| A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. | Cancer Discov | 2023 | 36264143 | PubTator, text mining | PubMed |
| SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. | J Thorac Oncol | 2023 | 36243387 | PubTator, text mining | PubMed |
| LncRNA MAFG-AS1-induced acute myeloid leukemia development via modulating miR-147b/HOXA9. | Environ Sci Pollut Res Int | 2023 | 36229729 | PubTator, text mining | PubMed |
| A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. | Haematologica | 2023 | 36226495 | PubTator, text mining | PubMed |
| HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells. | Bioact Mater | 2023 | 36185739 | PubTator, text mining | PubMed |
| HOXA9/MEIS1 targets in leukemia: reinforced signaling networks and therapeutic opportunities. | Haematologica | 2023 | 36005566 | PubTator, text mining | PubMed |
| Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia. | Haematologica | 2023 | 36005562 | PubTator, text mining | PubMed |
| Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern. | Drug Deliv Transl Res | 2023 | 35930221 | PubTator, text mining | PubMed |
| Analysis of rare driving events in pediatric acute myeloid leukemia. | Haematologica | 2023 | 35899387 | PubTator, text mining | PubMed |
| In Vivo Genome-Wide PGR Binding in Pregnant Human Myometrium Identifies Potential Regulators of Labor. | Reprod Sci | 2023 | 35732928 | PubTator, text mining | PubMed |
| Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice. | Blood Adv | 2023 | 35468619 | PubTator, text mining | PubMed |
| Molecular regulators of HOXA9 in acute myeloid leukemia. | FEBS J | 2023 | 34743404 | PubTator, text mining | PubMed |
| The diagnostic value of circulating tumor DNA in hepatitis B virus induced hepatocellular carcinoma: a systematic review and meta-analysis. | J Liver Cancer | 2022 | 37383408 | PubTator, text mining | PubMed |
| Annotation of Hox cluster and Hox cofactor genes in the Asian citrus psyllid, Diaphorina citri, reveals novel features. | GigaByte | 2022 | 36824511 | PubTator, text mining | PubMed |
| Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics. | Cell Genom | 2022 | 36777997 | PubTator, text mining | PubMed |
| Targeted Epigenetic Interventions in Cancer with an Emphasis on Pediatric Malignancies. | Biomolecules | 2022 | 36671446 | PubTator, text mining | PubMed |
| Effect of GATAD1 regulating the SRRM2 gene on recurrence of thyroid tumor and its molecular mechanism. | Gland Surg | 2022 | 36654960 | PubTator, text mining | PubMed |
| Prediction of prognosis and immunotherapy response of amino acid metabolism genes in acute myeloid leukemia. | Front Nutr | 2022 | 36618700 | PubTator, text mining | PubMed |
| Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool. | Int J Mol Sci | 2022 | 36614080 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3205/papers?page=30